ESH Video

EU Projects

Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemia Treatments

Making a difference in Rare Anaemia

CoMMiTMenT is a five-year Collaborative Project funded by the European Commission under the 7th Framework Programme of the European Union. The project aims to develop combined imaging technologies based on optofluidic microscopy and scanning ion conductance microscopy. An integrated, completely simultaneous device named µCOSMOS will be used as a proof-of-principle for therapeutic interventions in rare anaemias. Therefore, CoMMiTMenT contributes to the goal of the International Rare Diseases Research Consortium (IRDiRC) to deliver novel diagnostic modalities and 200 new therapies for rare diseases by 2020. The CoMMiTMenT consortium combines outstanding expertise from successfully operating, research-intensive SMEs and leading academic institutions. In addition, the consortium includes clinical partners and builds a strong relationship with the European Network for Rare and Congenital Anaemias (ENERCA).
ITN “EuroCSCTraining”

ITN “EuroCSCTraining”(2010-2015) The European Cancer Stem Cell Consortium provides an excellent platform for a dedicated EuroCancerStemCell Network for training young researchers in the field. 9 Organisms of this CSC consortium from 6 member states all with a similar dedication to ER and ESR training have decided to create a specific cross Europe training platform for cancer stem cell research (EuroCSCTraining Network). To complement their training they have solicited the participation of not less than 8 associate partners including front line enterprises of the field who have all extreme dedication to training and career description.

The treatment of malignancies has greatly benefited from increased knowledge in the Biology of Cancer. Identification of signalling pathways has generated targeted therapies that now yield measurable survival advantage for cancer patients while molecular signatures have improved prognostic classification. In an NCI report, cancer remission rates are shown to have increased over the past two decades (htpp:// Thus unravelling the signalling pathways and the key molecules, which participate in the production and survival of cancer cells has greatly improved the survival and quality of life of cancer patients. However, despite these improvements cancer patients still relapse and overall survival at five years remains poor.

The identification of the cancer stem cell, CSC (or Tumour Initiating Cell) in most cancers opens a novel topic in Cancer Biology, which should provide novel targets for cancer management and provide new hope for survival or cure. Indeed, it has already been shown that the stemness characteristics, which the CSC shares with its normal counterpart such as quiescence, may explain why relapses occur after conventional drugs such as radiotherapy and chemotherapy. Specifically targeting CSCs may provide a further level of cancer drug targeting. This requires an overall complete understanding of cancer stem cell biology. Nevertheless, this new field is still taking its marks both in terms of understanding and technology, stressing the necessity to work in well-structured networks.

European Network for Rare and Congenital Anaemias (ENERCA)
ENERCA is co-funded by the European Commission through its Public Health and Consumer Protection Directorate (DG SANCO), PHEA programme. The ENERCA Website contains information on rare and congenital anaemias. The contents of the site are being compiled with the assistance of the network participants.  The site intends to become a meeting point for the healthcare society wherever rare anaemias are diagnosed or suspected. The website is addressed to experts on these illnesses, health care professionals, research scientists, laboratory technicians and others who deal with the problems of recognising and diagnosing diseases related to blood health.  The extranet part of the ENERCA website has technical information for experts. ENERCA partners hope that online forums will become a meeting point for professionals to provide and receive support in caring for patients.  If you are a professional you can register now. The public part of the page is addressed to patients who suffer from rare anaemias, their families, and care providers. They will find descriptions of anaemias using everyday language.  There is also a list of Centres of Reference for different countries and illnesses so that you can find one near to where you live.
EMTACT (European Master in Transfusion Medicine and Advanced Cell Therapies)

ESH is a partner in the upcoming EMTACT online Masters Programme in Transfusion Medicine, Cellular and Tissue Therapies which was funded by the EC within the SOCRATES Program (ERASMUS – Joint Development of Study Programmes at intermediate and advanced level. The aim of the Master’s course and the postgraduate Diploma in Transfusion Medicine is to provide a broad training in Transfusion Medicine and associated fields so that students acquire the necessary skills to work in transfusion centres and also to carry out research in the related areas or develop technically qualified projects in the company sector. EMTACT brochure

European Network for Harmonization of Training in Hematology (H-Net)

H-Net is the acronym for the "European Network for Harmonization of Training in Hematology." (2008-2011) This project was awarded a grant under the Leonardo da Vinci Lifelong Learning Programme by the European Commission. In a joint effort of 26 partners, H-Net aims to arrive at a truly harmonized curriculum for European haematologists, thus raising the competence levels of haematologists and, ultimately, improving patient care and public health.

H-Net will build on the previously developed Curriculum Passport. This is an itemized description of what constitutes a well-rounded haematological training as recommended by national and international societies and organizations of haematology. H-Net will survey recently graduated haematologists and compare their qualifications to those expressed in the Curriculum Passport. Next, on the basis of the needs that derive from analyses of the survey data, H-Net will implement existing, and develop novel educational tools to meet those needs. An online portfolio system is being developed to allow individual haematologists to ascertain gaps in their training. Educational opportunities will be proposed to complete training gaps. For more information please click:


EUROCORD-ED: On-line curriculum on cord blood technology (2008-2011)

The European Commission awarded a grant to EUROCORD and the European School of Haematology to develop a comprehensive online training tool in the field of umbilical cord blood biology. This project named EUROCORD-ED brings together many major European partners including EHA, NETCORD, the European Network of cord blood banks, the EBMT, the cord blood banks in Milan, Madrid, Leiden and Athens, basic science research groups and the companies Biostór Ireland, Macopharma and Alcimed. The EUROCORD-ED project aims to inform and educate all the vocational actors involved in the field: laboratory scientists, technicians, clinicians, transplant physicians, obstetricians, midwives and biotechnology companies involved in banking, research, and the clinical analysis of cord blood and ICT. EUROCORD-ED also aims to inform future parents, and to support health policy decision makers.

All establishments involved in cord blood processing now need to be licensed and people need to be trained in the requirements of the Directives and Good Manufacturing Practice (GMP). This project will build on previous European Commission grants awarded to EUROCORD and ESH related to training, mobility and quality control in the healthcare setting. For more information please visit: